MA33090B1 - Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer - Google Patents
Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au ferInfo
- Publication number
- MA33090B1 MA33090B1 MA34119A MA34119A MA33090B1 MA 33090 B1 MA33090 B1 MA 33090B1 MA 34119 A MA34119 A MA 34119A MA 34119 A MA34119 A MA 34119A MA 33090 B1 MA33090 B1 MA 33090B1
- Authority
- MA
- Morocco
- Prior art keywords
- iron
- deferiprone
- prevention
- treatment
- eye disorders
- Prior art date
Links
- TZXKOCQBRNJULO-UHFFFAOYSA-N Ferriprox Chemical compound CC1=C(O)C(=O)C=CN1C TZXKOCQBRNJULO-UHFFFAOYSA-N 0.000 title abstract 5
- 229960003266 deferiprone Drugs 0.000 title abstract 5
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 8
- 229910052742 iron Inorganic materials 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention porte sur l'utilisation de défériprone disponible par voie orale ou appliquée par voie topique pour la prévention d'un dommage oculaire induit par le fer. L'utilisation peut avoir pour but la préparation d'un médicament ou un procédé consistant à empêcher un dommage oculaire lié au fer à un Sil d'un sujet à risque ce qui concerne un dommage oculaire induit par le fer, le procédé comprenant l'administration d'une quantité prophylactiquement efficace de défériprone au sujet. L'invention porte également sur l'utilisation de défériprone pour le traitement de troubles oculaires liés au fer. L'utilisation peut avoir pour but la préparation d'un médicament ou un procédé de traitement d'un dommage à un Sil souffrant d'un dommage oculaire associé au fer, le procédé comprenant l'administration topique d'une quantité thérapeutiquement efficace de défériprone au sujet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14724509P | 2009-01-26 | 2009-01-26 | |
| PCT/CA2009/001639 WO2010083582A1 (fr) | 2009-01-26 | 2009-11-12 | Utilisation de défériprone pour le traitement et la prévention de troubles oculaires liés au fer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33090B1 true MA33090B1 (fr) | 2012-03-01 |
Family
ID=42355449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34119A MA33090B1 (fr) | 2009-01-26 | 2009-11-12 | Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130023569A1 (fr) |
| EP (1) | EP2389179A4 (fr) |
| JP (1) | JP5604631B2 (fr) |
| KR (1) | KR20120078667A (fr) |
| CN (1) | CN102348456A (fr) |
| AP (1) | AP2011005843A0 (fr) |
| AU (1) | AU2009338093B2 (fr) |
| BR (1) | BRPI0920492A2 (fr) |
| CA (1) | CA2750599A1 (fr) |
| CL (1) | CL2011001812A1 (fr) |
| CR (1) | CR20110456A (fr) |
| EA (1) | EA201170970A1 (fr) |
| IL (1) | IL214291A (fr) |
| MA (1) | MA33090B1 (fr) |
| MX (1) | MX2011007947A (fr) |
| MY (1) | MY161269A (fr) |
| NI (1) | NI201100148A (fr) |
| NZ (1) | NZ594728A (fr) |
| PE (1) | PE20120515A1 (fr) |
| SG (1) | SG173145A1 (fr) |
| TN (1) | TN2011000366A1 (fr) |
| UA (1) | UA103366C2 (fr) |
| WO (1) | WO2010083582A1 (fr) |
| ZA (1) | ZA201105514B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6725515B2 (ja) * | 2015-01-09 | 2020-07-22 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | 小分子を用いた鉄欠乏生物における生理機能の回復 |
| MD3684344T2 (ro) | 2017-10-25 | 2025-09-30 | Chiesi Farm Spa | Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6046219A (en) * | 1995-01-20 | 2000-04-04 | Cornell Research Foundation, Inc. | Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation |
| US5674888A (en) * | 1995-06-07 | 1997-10-07 | University Of California | Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division |
| AUPQ262499A0 (en) * | 1999-09-02 | 1999-09-23 | University Of Queensland, The | Novel iron chelators |
| EP1565185A4 (fr) * | 2002-11-07 | 2011-01-05 | Technion Res & Dev Foundation | Chelateurs du fer et compositions pharmaceutiques les renfermant |
| EP1601367A2 (fr) * | 2003-02-06 | 2005-12-07 | Bioresponse L.L.C. | Utilisation combinee d'indoles cruciferes et de chelateurs pour le traitement d'etats lies au papillomavirus |
| WO2007095728A1 (fr) * | 2006-02-22 | 2007-08-30 | Arnold Munnich | Utilisation de défériprone et méthodes de traitement prophylactique et/ou thérapeutique de la maladie de friedreich résultant d'un dysfonctionnement du traitement intracellulaire du fer |
| CN101534826A (zh) | 2006-04-14 | 2009-09-16 | 普拉纳生物技术有限公司 | 治疗与年龄相关的黄斑变性（amd）的方法 |
| ITMI20061770A1 (it) * | 2006-09-18 | 2008-03-19 | Carlo Ghisalberti | Metodo cosmetico di riduzione delle occhiaie |
| US8501789B2 (en) * | 2007-01-19 | 2013-08-06 | The Trustees Of The University Of Pennsylvania | Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease |
-
2009
- 2009-11-12 CA CA2750599A patent/CA2750599A1/fr not_active Abandoned
- 2009-11-12 SG SG2011053972A patent/SG173145A1/en unknown
- 2009-11-12 AU AU2009338093A patent/AU2009338093B2/en not_active Ceased
- 2009-11-12 WO PCT/CA2009/001639 patent/WO2010083582A1/fr not_active Ceased
- 2009-11-12 EP EP09838587A patent/EP2389179A4/fr not_active Withdrawn
- 2009-11-12 CN CN2009801579837A patent/CN102348456A/zh active Pending
- 2009-11-12 KR KR1020117019874A patent/KR20120078667A/ko not_active Withdrawn
- 2009-11-12 MY MYPI2011003478A patent/MY161269A/en unknown
- 2009-11-12 PE PE2011001408A patent/PE20120515A1/es not_active Application Discontinuation
- 2009-11-12 EA EA201170970A patent/EA201170970A1/ru unknown
- 2009-11-12 US US13/138,263 patent/US20130023569A1/en not_active Abandoned
- 2009-11-12 JP JP2011546542A patent/JP5604631B2/ja not_active Expired - Fee Related
- 2009-11-12 AP AP2011005843A patent/AP2011005843A0/xx unknown
- 2009-11-12 BR BRPI0920492A patent/BRPI0920492A2/pt not_active IP Right Cessation
- 2009-11-12 UA UAA201110546A patent/UA103366C2/ru unknown
- 2009-11-12 NZ NZ594728A patent/NZ594728A/xx unknown
- 2009-11-12 MX MX2011007947A patent/MX2011007947A/es not_active Application Discontinuation
- 2009-11-12 MA MA34119A patent/MA33090B1/fr unknown
-
2011
- 2011-07-26 TN TN2011000366A patent/TN2011000366A1/fr unknown
- 2011-07-26 ZA ZA2011/05514A patent/ZA201105514B/en unknown
- 2011-07-26 CL CL2011001812A patent/CL2011001812A1/es unknown
- 2011-07-26 NI NI201100148A patent/NI201100148A/es unknown
- 2011-07-26 IL IL214291A patent/IL214291A/en not_active IP Right Cessation
- 2011-08-24 CR CR20110456A patent/CR20110456A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201170970A1 (ru) | 2012-03-30 |
| IL214291A0 (en) | 2011-09-27 |
| CN102348456A (zh) | 2012-02-08 |
| MY161269A (en) | 2017-04-14 |
| TN2011000366A1 (en) | 2013-03-27 |
| ZA201105514B (en) | 2012-10-31 |
| NI201100148A (es) | 2012-03-06 |
| EP2389179A4 (fr) | 2012-08-29 |
| IL214291A (en) | 2015-03-31 |
| NZ594728A (en) | 2013-03-28 |
| SG173145A1 (en) | 2011-08-29 |
| MX2011007947A (es) | 2011-12-14 |
| UA103366C2 (ru) | 2013-10-10 |
| KR20120078667A (ko) | 2012-07-10 |
| PE20120515A1 (es) | 2012-05-20 |
| AU2009338093A1 (en) | 2011-09-08 |
| CL2011001812A1 (es) | 2012-02-03 |
| CA2750599A1 (fr) | 2010-07-29 |
| AU2009338093B2 (en) | 2014-08-28 |
| AP2011005843A0 (en) | 2011-08-31 |
| US20130023569A1 (en) | 2013-01-24 |
| JP2012515725A (ja) | 2012-07-12 |
| JP5604631B2 (ja) | 2014-10-08 |
| EP2389179A1 (fr) | 2011-11-30 |
| CR20110456A (es) | 2012-05-31 |
| BRPI0920492A2 (pt) | 2019-07-09 |
| WO2010083582A1 (fr) | 2010-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57825B1 (fr) | Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques | |
| MA38576A1 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
| MA44764A (fr) | Méthodes de traitement de patients présentant une hypercholestérolémie familiale | |
| MA46430B1 (fr) | Thérapie combinée d'agonistes de cnp à libération contrôlée | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MX2007005570A (es) | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos. | |
| FR3065371B1 (fr) | Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques peripheriques | |
| WO2011047439A8 (fr) | Nouvelle thérapie antiparasitaire | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| MA33090B1 (fr) | Utilisation de deferiprone pour le traitement et la prevention de troubles oculaires lies au fer | |
| ATE554770T1 (de) | Therapeutisches mittel gegen entzündliche darmerkrankungen | |
| WO2008021970A3 (fr) | Traitement d'une maladie des motoneurones, incluant certains troubles neurologiques, des neuropathies motrices et des maladies inflammatoires chroniques | |
| MA38425B1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MA34106B1 (fr) | Combinaison de composés organiques | |
| EP1773374A4 (fr) | Agent comprenant le fgf2 comme ingredient actif pour le traitement ou la prevention de l'asthme et de la bronchopneumopathie chronique obstructive | |
| EP2005194A4 (fr) | Procédés utilisant de l'hémoglobine pour la prophylaxie, le diagnostic et/ou le traitement de troubles de la rétine | |
| MA31902B1 (fr) | Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque | |
| TN2010000108A1 (fr) | Traitement de symtomes vasomoteurs | |
| WO2009131850A3 (fr) | Inhibiteurs de l’expression et de l’activité de pai-1 pour le traitement des troubles oculaires | |
| FR3070261B1 (fr) | Produit de combinaison pour soulager les symptomes lies aux infections des voies respiratoires superieures | |
| FI4048249T3 (fi) | Menetelmiä autismikirjon häiriön oireiden hoitamiseksi | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| WO2003103699A8 (fr) | Utilisation de ramoplanine pour traiter des troubles associes a la prise d'antibiotiques |